TerminatedPhase 3ketamine

Ketamine in Refractory Convulsive Status Epilepticus

Sponsored by Meyer Children's Hospital IRCCS

NCT ID
NCT02431663
Target Enrollment
57 participants
Start Date
2015-04
Est. Completion
2020-03-31

About This Study

To evaluate the efficacy of intravenous administration of ketamine in the treatment of refractory convulsive status epilepticus in children compared to administration of midazolam at high doses, thiopental and / or propofol.

Conditions Studied

Status Epilepticus

Interventions

  • Ketamine

Eligibility

Age:1 Month - 18 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Diagnosis and clinical EEGrafica of refractory convulsive status epilepticus
* Refractoriness of the drug I and II line
* Written informed consent from parents or legal guardian.
* Administration of rating scales in the risk of mortality (PIM III) and severity of SE (stess, status epilepticusseverity score) to be performed prior to randomization.

Exclusion Criteria:

* contraindications to the use of the medication/s in the study.
* pregnant or suspected pregnant.

Study Locations (1)

Anna Rosati
Florence, Italy

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source